Literature DB >> 6271839

Treatment of human spasticity with delta 9-tetrahydrocannabinol.

D J Petro, C Ellenberger.   

Abstract

Spasticity is a common neurologic condition in patients with multiple sclerosis, stroke, cerebral palsy or an injured spinal cord. Animal studies suggest that THC has an inhibitory effect on polysynaptic reflexes. Some spastic patients claim improvement after inhaling cannabis. We tested muscle tone, reflexes, strength and performed EMGs before and after double-blinded oral administration of either 10 or 5 mg THC or placebo. The blinded examiner correctly identified the trials in which the patients received THC in seven of nine cases. For the group, 10 mg THC significantly reduced spasticity by clinical measurement (P less than 0.01). Quadriceps EMG interference pattern was reduced in those four patients with primarily extensor spasticity. THC was administered to eight other patients with spasticity and other CNS lesions. Responses varied, but benefit was seen in three of three patients with "tonic spasms." No benefit was noted in patients with cerebellar disease.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6271839     DOI: 10.1002/j.1552-4604.1981.tb02621.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  34 in total

Review 1.  Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review.

Authors:  F A Campbell; M R Tramèr; D Carroll; D J Reynolds; R A Moore; H J McQuay
Journal:  BMJ       Date:  2001-07-07

Review 2.  [The endogenous cannabinoid system. Therapeutic implications for neurologic and psychiatric disorders].

Authors:  U Schneider; J Seifert; M Karst; J Schlimme; K Cimander; K R Müller-Vahl
Journal:  Nervenarzt       Date:  2005-09       Impact factor: 1.214

3.  Cannabinoids in pain management. Study was bound to conclude that cannabinoids had limited efficacy.

Authors:  E Russo
Journal:  BMJ       Date:  2001-11-24

Review 4.  Pharmacokinetics and pharmacodynamics of cannabinoids.

Authors:  Franjo Grotenhermen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

5.  Effect of cannabinoids on spasticity and ataxia in multiple sclerosis.

Authors:  H M Meinck; P W Schönle; B Conrad
Journal:  J Neurol       Date:  1989-02       Impact factor: 4.849

Review 6.  [Therapeutic use of cannabinoids in neurology].

Authors:  P Schwenkreis; M Tegenthoff
Journal:  Schmerz       Date:  2003-10       Impact factor: 1.107

Review 7.  Cannabinoid-based medicines for neurological disorders--clinical evidence.

Authors:  Stephen Wright
Journal:  Mol Neurobiol       Date:  2007-06-29       Impact factor: 5.590

Review 8.  Cannabinoids and multiple sclerosis.

Authors:  Roger G Pertwee
Journal:  Mol Neurobiol       Date:  2007-06-26       Impact factor: 5.590

Review 9.  Cannabinoids in multiple sclerosis: do they have a therapeutic role?

Authors:  Joep Killestein; Bernard M J Uitdehaag; Chris H Polman
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 10.  The therapeutic potential of cannabis and cannabinoids.

Authors:  Franjo Grotenhermen; Kirsten Müller-Vahl
Journal:  Dtsch Arztebl Int       Date:  2012-07-23       Impact factor: 5.594

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.